COVID-19 (severe/fatal) |
Laboratory Findings |
Total bilirubin [Abnormal vs. Normal] |
Hazard ratio: 2.250 (0.940-5.350)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
AST [Abnormal vs. Normal] |
Hazard ratio: 2.200 (1.100-6.730)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Laboratory Findings |
Procalcitonin [Abnormal vs. Normal] |
Hazard ratio: 8.720 (3.420-22.280)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Symptoms |
Dyspnea [Present vs. Not present] |
Hazard ratio: 3.960 (1.420-11.000)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Cerebrovascular disease [Present vs. Not present] |
Hazard ratio: 3.100 (1.070-8.940)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Coronary heart disease [Present vs. Not present] |
Hazard ratio: 4.280 (1.140-16.130)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [>=75 years vs. <65 years] |
Hazard ratio: 7.860 (2.440-25.350)
§ |
Chen
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [65-74 years vs. <65 years] |
Hazard ratio: 3.430 (1.240-9.500)
§ |
Chen
|
|
|
COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Ribavirin received vs. Not received] |
Hazard ratio: 1.420 (0.670-3.030)
§ |
Wang
|
|
|
COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Arbidol received vs. Not received] |
Hazard ratio: 0.500 (0.300-0.840)
§ |
Wang
|
|
|
COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Treated with Lopinavir–Ritonavir vs. Not received] |
Hazard ratio: 0.350 (0.150-0.830)
§ |
Wang
|
|
|
COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Low-dose glucocorticoid received (<1mg/kg) vs. High-dose glucocorticoid received (>=1mg/kg)] |
Hazard ratio: 0.530 (0.310-0.900)
§ |
Wang
|
|
|
COVID-19 (death) |
Treatment |
Treatment for COVID-19 [Glucocorticoid not received vs. High-dose glucocorticoid received (>=1mg/kg)] |
Hazard ratio: 0.410 (0.190-0.860)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
Lymphocyte time [Abnormal vs. Normal] |
Hazard ratio: 0.730 (0.620-0.860)
§ |
Wang
|
|
|
COVID-19 (death) |
Complications |
Multi-organ dysfunction [Present vs. Normal] |
Hazard ratio: 1.270 (1.040-1.570)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
LDH [250–445U/L vs. >=445U/L] |
Hazard ratio: 0.290 (0.160-0.520)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
LDH [<250U/L vs. >=445U/L] |
Hazard ratio: 0.070 (0.010-0.560)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
Lymphocyte count [Abnormal vs. Normal] |
Hazard ratio: 4.410 (1.380-14.140)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
WBC [4×10^9–10×10^9/L vs. >10×10^9/L] |
Hazard ratio: 0.560 (0.320-0.950)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
WBC [<4×10^9/L vs. >10×10^9/L] |
Hazard ratio: 0.700 (0.270-1.850)
§ |
Wang
|
|
|
COVID-19 (death) |
Laboratory Findings |
Oxygen Saturation (SaO2) [>=93% vs. <93%] |
Hazard ratio: 0.320 (0.180-0.550)
§ |
Wang
|
|
|
COVID-19 (death) |
Patient characteristics |
Age [>65 years vs. <=65 years] |
Hazard ratio: 1.960 (1.180-3.250)
§ |
Wang
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Ischaemic heart disease and heart failure [Present vs. Not present] |
Odds ratio: 0.530 (0.180-1.400)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Hypertension [Present vs. Not present] |
Odds ratio: 2.100 (0.900-4.800)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Diabetes [Present vs. Not present] |
Odds ratio: 1.500 (0.710-3.000)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 2.000 (1.000-4.000)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [10 year increase vs. Not applicable] |
Odds ratio: 1.000 (0.850-1.300)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with ACEi vs. Not received] |
Odds ratio: 0.290 (0.100-0.750)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 2.000 (1.000-3.900)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [10 year increase vs. Not applicable] |
Odds ratio: 1.000 (0.820-1.200)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Comorbidities |
Hypertension [Present vs. Not present] |
Odds ratio: 2.200 (1.000-4.900)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with ACEi vs. Not received] |
Odds ratio: 0.280 (0.090-0.730)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Gender [Male vs. Female] |
Odds ratio: 1.800 (0.950-3.400)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [10 year increase vs. Not applicable] |
Odds ratio: 1.100 (0.940-1.300)
§ |
Bean
|
|
|
COVID-19 (severe/fatal) |
Treatment |
Concomitant medication [Treated with ACEi vs. Not received] |
Odds ratio: 0.340 (0.110-0.860)
§ |
Bean
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
BMI [Severe obesity (>35kg/m2) vs. Non-obese (BMI<30)] |
Odds ratio: 3.600 (2.500-5.300)
|
Lighter
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
BMI [Obesity (30-35kg/m2) vs. Non-obese (BMI<30)] |
Odds ratio: 1.800 (1.200-2.700)
|
Lighter
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
BMI [Severe obesity (>35kg/m2) vs. Non-obese (BMI<30)] |
Odds ratio: 1.500 (0.900-2.300)
|
Lighter
|
|
|
COVID-19 (severe/critical) |
Patient characteristics |
BMI [Obesity (30-35kg/m2) vs. Non-obese (BMI<30)] |
Odds ratio: 1.100 (0.800-1.700)
|
Lighter
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Age [1 year increase vs. Not applicable] |
Hazard ratio: 1.460 (0.480-4.430)
§ |
Zhang
|
|
|
COVID-19 (severe/fatal) |
Patient characteristics |
Gender [Male vs. Female] |
Hazard ratio: 0.570 (0.160-2.040)
§ |
Zhang
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
Fibrinogen [Abnormal vs. Normal] |
Odds ratio: 1.061 (0.599-1.877)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
IL-6 [Abnormal vs. Normal] |
Odds ratio: 1.007 (0.990-1.024)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
LDH [Abnormal vs. Normal] |
Odds ratio: 0.996 (0.990-1.006)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
CD8 [Abnormal vs. Normal] |
Odds ratio: 1.002 (0.998-1.006)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
CD4 [Abnormal vs. Normal] |
Odds ratio: 0.996 (0.992-1.000)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
NLR [Abnormal vs. Normal] |
Odds ratio: 1.104 (0.724-1.684)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
CRP [Abnormal vs. Normal] |
Odds ratio: 0.991 (0.970-1.013)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
Albumin [Abnormal vs. Normal] |
Odds ratio: 0.850 (0.700-1.020)
§ |
Wei
|
|
|
COVID-19 (severe/critical) |
Laboratory Findings |
Lymphocyte ratio [1% decrease vs. Normal] |
Odds ratio: 1.040 (0.920-1.170)
§ |
Wei
|
|
|